Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11973MR)

This product GTTS-WQ11973MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11973MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7570MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ3010MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ301MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ6416MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ8783MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ3712MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ15019MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ9110MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW